One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Discover OPKO Health's Q2 2025 earnings insights, highlighting asset sales, cost savings, and pipeline advancements.

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting ...

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

By the end of 2024, Axmed had partnered with over 20 organizations across 15 countries. It processed more than 4,200 orders, ...

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...